Am I Catching a Falling Knife?

Walmart stock is down nearly 8% in just 10 days—but is this a breakout or a trap? In this episode of Am I Catching a Falling Knife?, we dissect the bullish narrative around resilient sales growth and expose the margin pressures that could undermine it. Using real numbers, DCF models, and PEG ratios, we reveal why Walmart’s current price may be dangerously optimistic. 📊 Topics Covered: • Walmart’s...

Step into today’s Daily Market Narrative, where we decode the post‑Jackson Hole risk‑on frenzy without the financial jargon. 📉 Powell hints at rate cuts — markets cheer, SPY charts sparkle. 📈 Corporate earnings are up, consumer fears down… but is it all built on shaky Jenga blocks? Plus: Private credit default warnings 🚨 Nvidia halts H20 chip production 🤖 Tariff confusion freezes mail deliveri...

Is Palantir Technologies (PLTR) a misunderstood AI titan—or just another overhyped tech stock? In this episode of Am I Catching a Falling Knife?, Dave breaks down Palantir’s recent pullback, its ambitious AI platforms like Gotham, Foundry, and AIP, and the market’s growing skepticism around its valuation. We run a full DCF analysis, explore Wall Street’s shifting sentiment, and reveal our narrativ...

Is Target (TGT) the ultimate bargain — or a dangerous value trap? In this episode of Am I Catching a Falling Knife?, we dissect the market narrative, Q2 2025 earnings miss, consumer spending trends, and the CEO transition shaking investor confidence. What you'll learn: Why discretionary spending weakness is hitting TGT The real impact of operating leverage on earnings DCF valuation & fair...

Cisco Systems (CSCO) just took a 10% nosedive after its Q2 FY2025 earnings — but is this a falling knife or a hidden gem? In this episode of Am I Catching a Falling Knife?, we break down the revenue miss, margin compression, and future guidance to uncover whether Cisco is a value trap or a long-term buy. 🔍 What you'll learn: Why Cisco stock dropped 10% Key financial metrics and valuation mode...

Is AMAT a hidden gem or a dangerous trap? In this episode of Am I Catching a Falling Knife?, we break down the recent 10% plunge in Applied Materials stock and uncover the real story behind its cautious Q4 outlook. From China’s geopolitical headwinds to the AI-driven future of semiconductors, we analyze AMAT’s fundamentals, revenue breakdown, and valuation models to help you decide: is this the mo...

Deere & Company (NYSE: DE) just dropped 22% after slashing its earnings outlook. Is this a golden buying opportunity or a dangerous trap? In this episode of Am I Catching a Falling Knife?, we break down the Q3 2025 earnings miss, margin compression, and cyclical headwinds hitting the ag giant. We analyze valuation, risks, and three key buy levels to watch. Don’t miss this deep dive into one of...

Tapestry (TPR) just took a jaw‑dropping hit — plunging after weak earnings and slashed guidance. In this deep‑dive breakdown, we’ll uncover the hard‑hitting reasons behind the drop, from margin pressure and inventory build‑up to shifting consumer demand in key markets. Then we’ll put TPR under the microscope with a full financial statement review, discounted cash flow valuation, and peer compariso...

CAVA just dropped ~10% after earnings on slowing same‑store sales and lowered guidance — despite beating on EPS and revenue. Is this a real opportunity or a classic falling knife? I break down the narrative, run a quick DCF vs PEG, and share my buy zones. What happened: EPS/rev beat, but growth narrative cracked on SSS slowdown and guidance trim. Numbers that matter: 398 stores, ~$954.3M TTM reven...

Cardinal Health (CAH) just dropped over 7% after Q4 FY2025 results and a $1.9B Solaris Health acquisition. Is this a falling knife… or a setup for a smarter entry? In this episode, we break down the revenue miss, thin 3.53% gross margins, financing risk, DCF and PEG valuations, and my buy levels based on a net −6.5% near-term earnings impact. Key points: EPS/guidance up, but revenue miss + deal fi...

When a stock drops 38.7% in days after beating earnings and raising guidance… you have to ask: did the story break, or did expectations snap? In this episode of “Am I Catching a Falling Knife?”, we dig into monday.com (MNDY): what they actually do, why Q3 “conservative” outlook spooked the Street, how 90% gross margins amplify narrative shocks, and what a 7.5% near-term earnings reset means for va...

Is Lululemon (LULU) stock in freefall—or is this the perfect time to buy the dip? In this episode of Am I Catching a Falling Knife?, Dave breaks down the recent 13.92% drop in LULU’s share price and dives deep into the numbers behind the headlines. From softening U.S. consumer spending to tariff impacts, we quantify the narrative and estimate a potential -10.4% hit to quarterly earnings. Using DCF...

Under Armour (UA) just dropped 23.45%. Are we catching a falling knife or a rare value setup? In this episode, we break down the narrative (North America weakness, weak guidance, downgrades), quantify the hit (estimated 15% quarterly earnings decline via operating leverage), and stack valuations: DCF base ≈ $5.19 vs narrative case ≈ $4.15 and PEG-implied ≈ $4.46. We also map buy zones at $4.40, $4...

🎯 Title TTD Stock CRASHED 37% — Is This a Buy or a Total Trap? | Falling Knife Analysis 📝 Description Is The Trade Desk (TTD) a discounted gem or a financial disaster waiting to happen? In this episode of Am I Catching a Falling Knife?, we dissect TTD’s brutal 37% drop, break down the Q2 earnings drama, and run the numbers on valuation, margins, and operating leverage. With high fixed costs and...

Fortinet (FTNT) just tanked 28% — but is this cybersecurity giant a hidden gem or a value trap? In this episode of Am I Catching a Falling Knife?, Dave breaks down the real reasons behind the drop: slowing service revenue, SASE cannibalization fears, and analyst downgrades. We run the numbers with DCF and PEG models to reveal Fortinet’s true value — and share custom buy levels for risk-savvy inves...

Eli Lilly (LLY) just dropped over 20% — but is it panic or opportunity? In this episode of Am I Catching a Falling Knife?, we dissect the GLP-1 drama, break down the earnings impact, and run valuation models to see if this pharma giant is oversold or overhyped. 🔍 Topics covered: What happened with orforglipron How investor sentiment affects earnings DCF vs PEG valuation breakdown 📉 Not financial...

Is Airbnb (ABNB) a screaming buy—or a classic falling knife? In this episode of Am I Catching a Falling Knife?, Dave breaks down the recent dip in Airbnb’s stock price and uncovers the real story behind the cautious outlook, margin pressures, and valuation disconnect. 🔍 What you'll learn: Why Airbnb’s strong Q2 earnings aren’t saving the stock How increased investments could slash profits by...

Is The Mosaic Company (MOS) a hidden gem or a financial landmine? In this episode of Am I Catching a Falling Knife?, we dissect MOS’s brutal 16.81% drop following its Q2 2025 earnings miss. We break down:What Mosaic actually does (hint: it’s all about crop nutrients)Why Wall Street got it wrongHow future earnings could take a 6% hitOur DCF and PEG-based valuationsCustom buy levels for brave invest...

NRG Energy just dropped over 10%—but is it panic time or a rare buying opportunity? In this episode of Am I Catching a Falling Knife?, Dave breaks down the brutal investor reaction to NRG’s underwhelming data center deals, crunches the numbers on revenue impact, and reveals custom buy levels that could be game-changers.📉 Is this a falling knife or a misunderstood power play? Tune in and decide.👉...

Hims & Hers Health (HIMS) just got wrecked after missing Q2 revenue and triggering major concerns around its GLP-1 weight-loss pipeline. Is this a rare buying opportunity—or a regulatory disaster in disguise? Join Dave on "Am I Catching a Falling Knife?" as we deep dive into: 👉 Market narrative vs fundamentals 👉 DCF and PEG valuation models 👉 Buy zones for risk-tolerant traders Th...

ON Semiconductor just dropped over 20%—but is it really a falling knife, or a deep-value play in disguise? In this episode of *Am I Catching a Falling Knife?*, host Dave cuts through the hype and dives deep into ON’s latest earnings, sector pressures, and hidden opportunities. With sharp DCF models and PEG-based reality checks, we expose the wild gap between ON’s current price and its intrinsic va...

Coinbase just dropped nearly 24% — but is this the moment to buy the dip or avoid a deeper dive? In this episode of **Am I Catching a Falling Knife?**, we break down the numbers behind COIN’s Q2 earnings, analyze key revenue segments, and run a narrative-adjusted DCF model to find out if this knife is worth catching. With retail traders pulling back and Coinbase doubling down on institutions, is t...

Eastman Chemical (EMN) nosedived 24.41% after missing earnings and slashing forecasts. But is the panic warranted—or is Wall Street ignoring a potential rebound? In this episode of Am I Catching a Falling Knife?, Dave unpacks EMN’s business breakdown, the macro threats from trade policy, and a stormy balance sheet with $5.13B in debt and negative cash flow. Get the full analysis—from earnings stum...

Accenture (ACN) just hit a 52-week low after a 9.69% drop—despite posting strong earnings and boosting its 2025 outlook. So what’s going on under the hood? In this episode of Am I Catching a Falling Knife?, Dave breaks down the market panic around new bookings, the ripple effect on earnings, and crunches two valuation models (DCF vs. PEG) to help you decide: bargain or blunder?🎧 Like, Subscribe &...

Cigna (CI) just took a scalpel to its chart—down 10% in ten days. But is this healthcare heavyweight bleeding out or quietly prepping for a rebound surgery? 💉In this episode of Am I Catching a Falling Knife?, Dave breaks down:🔍 The root causes of CI’s drop — specialty drug costs, regulatory pressure, and retention struggles 📉 Our estimate: a potential 11% quarterly earnings hit 💰 DCF vs PEG va...